Neil S Horowitz1, Alexi A Wright2. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, USA; Division of Medical Oncology, Dana Farber Cancer Institute, USA. Electronic address: nhorowitz@partners.org. 2. Division of Medical Oncology, Dana Farber Cancer Institute, USA.
Abstract
OBJECTIVE: To describe the effects of obesity on the pharmacokinetics and dosing of chemotherapies and provide recommendations for chemotherapy management in obese women with gynecologic malignancies. METHODS: PubMEd and MEDLINE databases were searched for articles published before June 2014. Only English-language articles were considered. 84 manuscripts were reviewed and 66 were included. Search terms included: obesity, overweight, body mass index, body surface area, glomerular filtration rate, chemotherapy, ovarian cancer, endometrial cancer, inflammation, and pharmacokinetics, RESULTS: Obese cancer patients have worse clinical outcomes, compared with non-obese patients. This may be because of differences in pharmacokinetics, metabolic dysregulation, or physicians' decisions to reduce chemotherapy dose-intensity during treatment to minimize toxicities. A 2012 American Society of Clinical Oncology Clinical Practice Guideline recommends using actual body weight for chemotherapy dosing in all patients treated with curative intent, irrespective of obesity, to avoid compromising clinical outcomes, including progression free survival (PFS) and overall survival (OS). In women with gynecologic cancers most studies demonstrate no difference in PFS or OS when obese patients receive the same chemotherapy dose intensity as non-obese patients, except perhaps with bevacizumab. CONCLUSIONS: Chemotherapy dose-intensity is a critical determinant of cancer outcomes and should be maintained in all patients, irrespective of obesity. Future studies should prospectively examine the impact of obesity on clinical outcomes (adverse events, survival) to improve the care of this growing population of patients who are at risk for inferior clinical outcomes.
OBJECTIVE: To describe the effects of obesity on the pharmacokinetics and dosing of chemotherapies and provide recommendations for chemotherapy management in obesewomen with gynecologic malignancies. METHODS: PubMEd and MEDLINE databases were searched for articles published before June 2014. Only English-language articles were considered. 84 manuscripts were reviewed and 66 were included. Search terms included: obesity, overweight, body mass index, body surface area, glomerular filtration rate, chemotherapy, ovarian cancer, endometrial cancer, inflammation, and pharmacokinetics, RESULTS:Obese cancerpatients have worse clinical outcomes, compared with non-obesepatients. This may be because of differences in pharmacokinetics, metabolic dysregulation, or physicians' decisions to reduce chemotherapy dose-intensity during treatment to minimize toxicities. A 2012 American Society of Clinical Oncology Clinical Practice Guideline recommends using actual body weight for chemotherapy dosing in all patients treated with curative intent, irrespective of obesity, to avoid compromising clinical outcomes, including progression free survival (PFS) and overall survival (OS). In women with gynecologic cancers most studies demonstrate no difference in PFS or OS when obesepatients receive the same chemotherapy dose intensity as non-obesepatients, except perhaps with bevacizumab. CONCLUSIONS: Chemotherapy dose-intensity is a critical determinant of cancer outcomes and should be maintained in all patients, irrespective of obesity. Future studies should prospectively examine the impact of obesity on clinical outcomes (adverse events, survival) to improve the care of this growing population of patients who are at risk for inferior clinical outcomes.
Authors: George Au-Yeung; Penelope M Webb; Anna DeFazio; Sian Fereday; Mathias Bressel; Linda Mileshkin Journal: Gynecol Oncol Date: 2014-04 Impact factor: 5.482
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Lieke H J Simkens; Miriam Koopman; Linda Mol; Gerrit Jan Veldhuis; Daan Ten Bokkel Huinink; Erik W Muller; Veerle A Derleyn; Steven Teerenstra; Cornelis J A Punt Journal: Eur J Cancer Date: 2011-07-29 Impact factor: 9.162
Authors: Wendy Demark-Wahnefried; Elizabeth A Platz; Jennifer A Ligibel; Cindy K Blair; Kerry S Courneya; Jeffrey A Meyerhardt; Patricia A Ganz; Cheryl L Rock; Kathryn H Schmitz; Thomas Wadden; Errol J Philip; Bruce Wolfe; Susan M Gapstur; Rachel Ballard-Barbash; Anne McTiernan; Lori Minasian; Linda Nebeling; Pamela J Goodwin Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-13 Impact factor: 4.254
Authors: Carmen Rodriguez; Eugenia E Calle; Dorna Fakhrabadi-Shokoohi; Eric J Jacobs; Michael J Thun Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-09 Impact factor: 4.254
Authors: A Smits; J McGrane; A Lopes; E Kent; R Bekkers; L Massuger; N Simpson; K Galaal Journal: Int J Clin Oncol Date: 2017-06-15 Impact factor: 3.402
Authors: Daniel Shepshelovich; Wei Xu; Lin Lu; Aline Fares; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Xifeng Wu; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; M Catherine Brown; Geoffrey Liu; Rayjean J Hung Journal: J Thorac Oncol Date: 2019-06-01 Impact factor: 15.609
Authors: Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado Journal: Curr Oncol Rep Date: 2016-02 Impact factor: 5.075
Authors: Renée T Fortner; Elizabeth M Poole; Nicolas A Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Tess V Clendenen; Agnès Fournier; Gary Fraser; Susan M Gapstur; Mia M Gaudet; Graham G Giles; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Rudolf Kaaks; Victoria A Kirsh; Synnove Knutsen; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Maria-José Sánchez; Catherine Schairer; Leo J Schouten; Anne Tjonneland; Mary K Townsend; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Paolo Vineis; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Int J Cancer Date: 2019-01-14 Impact factor: 7.396
Authors: Cheryl E Myers; Dominique B Hoelzinger; Tiffany N Truong; Lindsey A Chew; Arpita Myles; Leena Chaudhuri; Jan B Egan; Jun Liu; Sandra J Gendler; Peter A Cohen Journal: Oncotarget Date: 2017-01-17